Novonesis is at the forefront of replacing traditional, fossil-based chemicals with nature-inspired enzymes and microbes. These solutions are applied across diverse industries like food, detergents, and biofuels, enabling benefits such as lower-temperature washing, cleaner food labels, and more efficient energy production.
The company's strength is built on a foundation of deep scientific expertise, including a massive library of microbial strains, significant R&D investment (10% of revenue), and global scale. Its products represent a small fraction of a customer's cost of goods (1-5%) but deliver immense value, creating high customer stickiness and pricing power.
Novonesis has integrated AI and advanced analytics deep into its R&D process, transforming its innovation capabilities. The company has reduced the time to predict a protein's shape after a single amino acid change from a year of lab work to mere seconds, drastically speeding up the development of new, high-performance solutions.
The company has successfully implemented a new pricing discipline, shifting from a historical 1-2% annual price erosion to a 1-2% annual price increase. This is achieved by systematically having conversations with customers about the shared value its products create, rather than only pricing at product launch.
The company's growth and product deployment are significantly influenced by varying regulatory timelines across the globe. For example, registering a microbe to replace a fertilizer can take six to eight years in Europe versus only two years in Brazil, creating different go-to-market speeds and strategic priorities.
Keep pulling the thread on Ester Baiget.